In the press

Matthew Read comments on NESF testing the market in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on NESF’s sale move in Michael Nelson’s article:

“There is no guarantee that NESF will attract a bid at an acceptable price, but NESF’s board finds itself in a difficult position and testing the market looks sensible although, like BSIF, we would be sorry to see NESF go.”

Read the article here